[
  {
    "ts": "2025-09-23T19:26:00+00:00",
    "headline": "Why Regeneron (REGN) Stock Is Down Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA.",
    "url": "https://finance.yahoo.com/news/why-regeneron-regn-stock-down-192600021.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "9e0d714c-b571-3e95-9151-c505104f32b9",
      "content": {
        "id": "9e0d714c-b571-3e95-9151-c505104f32b9",
        "contentType": "STORY",
        "title": "Why Regeneron (REGN) Stock Is Down Today",
        "description": "",
        "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA.",
        "pubDate": "2025-09-23T19:26:00Z",
        "displayTime": "2025-09-23T19:26:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "REGN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E5YeVaDzgHlFxvDwMx9gpg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6HLp77Q1Eazwpb8zaGf6Xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/863b7649ab1334021118a8518d7e40cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-regeneron-regn-stock-down-192600021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-regeneron-regn-stock-down-192600021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "REGN"
            },
            {
              "symbol": "SDZ.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T11:11:50+00:00",
    "headline": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall",
    "summary": "(Reuters) -Scholar Rock said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party manufacturing facility, sending the company's shares down 12% in premarket trading.  Scholar Rock is banking on apitegromab to drive its growth and profitability.  The drug is being tested as a treatment for spinal muscular atrophy and muscle preservation in obesity.",
    "url": "https://ca.finance.yahoo.com/news/us-fda-declines-approve-scholar-111150707.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "44615ebd-0122-3afd-b2c3-f2d30c425934",
      "content": {
        "id": "44615ebd-0122-3afd-b2c3-f2d30c425934",
        "contentType": "STORY",
        "title": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall",
        "description": "",
        "summary": "(Reuters) -Scholar Rock said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party manufacturing facility, sending the company's shares down 12% in premarket trading.  Scholar Rock is banking on apitegromab to drive its growth and profitability.  The drug is being tested as a treatment for spinal muscular atrophy and muscle preservation in obesity.",
        "pubDate": "2025-09-23T11:11:50Z",
        "displayTime": "2025-09-23T11:11:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/21adaf2aad122cf52c7351e0edfedca9",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qxNqWoFwYxVVplytPb0clw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/21adaf2aad122cf52c7351e0edfedca9.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X6ap9rnmiljzTx9UIYT73w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/21adaf2aad122cf52c7351e0edfedca9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://ca.finance.yahoo.com/news/us-fda-declines-approve-scholar-111150707.html",
          "site": "finance",
          "region": "CA",
          "lang": "en-CA"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-fda-declines-approve-scholar-111150707.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SRRK"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-23T11:11:50+00:00",
    "headline": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall",
    "summary": "(Reuters) -Scholar Rock said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party manufacturing facility, sending the company's shares down 12% in premarket trading.  Scholar Rock is banking on apitegromab to drive its growth and profitability.  The drug is being tested as a treatment for spinal muscular atrophy and muscle preservation in obesity.",
    "url": "https://finance.yahoo.com/news/us-fda-declines-approve-scholar-111150021.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "7e6fffed-cbc7-360b-93cd-c3b1bd74f145",
      "content": {
        "id": "7e6fffed-cbc7-360b-93cd-c3b1bd74f145",
        "contentType": "STORY",
        "title": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall",
        "description": "",
        "summary": "(Reuters) -Scholar Rock said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party manufacturing facility, sending the company's shares down 12% in premarket trading.  Scholar Rock is banking on apitegromab to drive its growth and profitability.  The drug is being tested as a treatment for spinal muscular atrophy and muscle preservation in obesity.",
        "pubDate": "2025-09-23T11:11:50Z",
        "displayTime": "2025-09-23T11:11:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters-finance.com/21adaf2aad122cf52c7351e0edfedca9",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "FILE PHOTO: Signage is seen outside of FDA headquarters in White Oak, Maryland",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/b8j7Is1LbKZAQrQFX7EJYg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/21adaf2aad122cf52c7351e0edfedca9.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kaHYLP935pDx0fj3khGr2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/21adaf2aad122cf52c7351e0edfedca9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/us-fda-declines-approve-scholar-111150021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/us-fda-declines-approve-scholar-111150021.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SRRK"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "REGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]